Erik S Musiek1. 1. Dept. of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis MO, USA.
Abstract
PURPOSE OF THE REVIEW: A wide array of sleep and circadian deficits have been observed in patients with Alzheimer's Disease (AD). However, the vast majority of these studies have focused on later-stage AD, and do not shed light on the possibility that circadian dysfunction contributes to AD pathogenesis. The goal of this review it to examine the evidence supporting or refuting the hypothesis that circadian dysfunction plays an important role in early AD pathogenesis or AD risk in humans. RECENT FINDINGS: Few studies have addressed the role of the circadian system in very early AD, or prior to AD diagnosis. AD appears to have a long presymtomatic phase during which pathology is present but cognition remains normal. Studies evaluating circadian function in cognitively-normal elderly or early-stage AD have thus far not incorporated AD biomarkers. Thus, the cause-and-effect relationship between circadian dysfunction and early-stage AD remains unclear. SUMMARY: Circadian dysfunction becomes apparent in AD as dementia progresses, but it is unknown at which point in the pathogenic process rhythms begin to deteriorate. Further, it is unknown if exposure to circadian disruption in middle age increases AD risk later in life. This review address gaps in current knowledge on this topic, and proposes several critical directions for future research which might help to clarify the potential pathogenic role of circadian clock dysfunction in AD.
PURPOSE OF THE REVIEW: A wide array of sleep and circadian deficits have been observed in patients with Alzheimer's Disease (AD). However, the vast majority of these studies have focused on later-stage AD, and do not shed light on the possibility that circadian dysfunction contributes to AD pathogenesis. The goal of this review it to examine the evidence supporting or refuting the hypothesis that circadian dysfunction plays an important role in early AD pathogenesis or AD risk in humans. RECENT FINDINGS: Few studies have addressed the role of the circadian system in very early AD, or prior to AD diagnosis. AD appears to have a long presymtomatic phase during which pathology is present but cognition remains normal. Studies evaluating circadian function in cognitively-normal elderly or early-stage AD have thus far not incorporated AD biomarkers. Thus, the cause-and-effect relationship between circadian dysfunction and early-stage AD remains unclear. SUMMARY: Circadian dysfunction becomes apparent in AD as dementia progresses, but it is unknown at which point in the pathogenic process rhythms begin to deteriorate. Further, it is unknown if exposure to circadian disruption in middle age increases AD risk later in life. This review address gaps in current knowledge on this topic, and proposes several critical directions for future research which might help to clarify the potential pathogenic role of circadian clock dysfunction in AD.
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: David G Harper; Edward G Stopa; Victoria Kuo-Leblanc; Ann C McKee; Kentaro Asayama; Ladislav Volicer; Neil Kowall; Andrew Satlin Journal: Brain Date: 2008-03-27 Impact factor: 13.501
Authors: Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski Journal: Acta Neuropathol Commun Date: 2013-10-09 Impact factor: 7.801
Authors: M J Duncan; L E Guerriero; K Kohler; L E Beechem; B D Gillis; F Salisbury; C Wessel; J Wang; S Sunderam; A D Bachstetter; B F O'Hara; M P Murphy Journal: Neuroscience Date: 2021-11-29 Impact factor: 3.590
Authors: Victoria M Pak; S-Hakki Onen; Donald L Bliwise; Nancy G Kutner; Katherine L Russell; Fannie Onen Journal: Front Aging Neurosci Date: 2020-05-08 Impact factor: 5.750
Authors: Allison R Fusilier; Jennifer A Davis; Jodi R Paul; Stefani D Yates; Laura J McMeekin; Lacy K Goode; Mugdha V Mokashi; Natalie Remiszewski; Thomas van Groen; Rita M Cowell; Lori L McMahon; Erik D Roberson; Karen L Gamble Journal: Neurobiol Dis Date: 2021-07-30 Impact factor: 5.996